National pharmacare – might it be a pig in a poke? Nigel Rawson and John Adams for Inside Policy
By Nigel Rawson and John Adams, May 28, 2024 No Canadian should have to choose between paying for medicines and ...
By Nigel Rawson and John Adams, May 28, 2024 No Canadian should have to choose between paying for medicines and ...
OTTAWA, ON (June 28, 2022): Is the Patented Medicine Prices Review Board (PMPRB) causing more harm than good? A recent ...
By Nigel Rawson and John Adams, March 24, 2022 Much has been written over the last few years about the ...
A new MLI commentary warns that pending and aggressive drug price control efforts could lead to major unintended consequences in ...
Advocates for national pharmacare who insist on control of drug prices, not by negotiation but by federal regulation, may have ...
While unconstitutional institutions and policies may be accommodated by the provinces to some degree, pushing them too far will end ...
By determinedly reducing revenues Canada not only ensures the unavailability of existing medications, it sees to it that far fewer ...
OTTAWA, ON (June 18, 2020): The COVID-19 pandemic has revealed numerous weaknesses in Canadian health care, and as the world ...
OTTAWA, ON (June 2, 2020): Changes to the Patented Medicine Prices Review Board (PMPRB) have been delayed until January 2021 ...
Lower ceiling prices for new medicines will make Canada less attractive as a country for new drugs and vaccines, making ...
An old idea for a short-cut to cheaper medicines in the US seems to be gaining momentum in 2019. President ...
Price-focused regulatory changes could limit access to new drugs and dampen R&D investment, writes Richard Owens. By Richard C. Owens, ...
|
Thank you for Signing Up |
323 Chapel Street, Suite #300
Ottawa, Ontario, K1N 7Z2 Canada
613.482.8327
Support the Macdonald-Laurier Institute to help ensure that Canada is one of the best governed countries in the world. Click below to learn more or become a sponsor.
© 2023 Macdonald-Laurier Institute. All Rights reserved.